Skip to main content
News

Emergent BioSolutions to acquire PaxVax and two travel vaccines in $270M deal | Fierce Pharma

By August 22, 2022No Comments
Jigsaw puzzle pieces on blue background 2021 08 26 22 35 31 utc

Jigsaw puzzle pieces on blue background 2021 08 26 22 35 31 utcAfter getting smallpox vaccine ACAM2000 from Sanofi and an anthrax treatment called raxibacumab from GlaxoSmithKline, Emergent BioSolutions is buying again, this time an entire company: PaxVax.

In an all-cash deal worth $270 million, Maryland-based Emergent, a vaccine company that has focused on biodefense, will buy California-headquartered specialty vaccine maker PaxVax, which also has close ties with the government.

 

{iframe}https://www.fiercepharma.com/vaccines/emergent-biosolutions-to-acquire-paxvax-and-two-travelers-vaccines-270m-deal{/iframe}

Leave a Reply

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.